Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Celgene
Celgene
Lyell Immunopharma, Inc.
Mayo Clinic
AstraZeneca
Gilead Sciences
Acerta Pharma BV
Stanford University
Medical University of South Carolina
Fate Therapeutics
M.D. Anderson Cancer Center
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Gustave Roussy, Cancer Campus, Grand Paris
Massachusetts General Hospital
The Second Affiliated Hospital of Fujian Medical University
University of Washington
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
University of Rochester
UNC Lineberger Comprehensive Cancer Center
Case Comprehensive Cancer Center
Celgene
Medical College of Wisconsin
City of Hope Medical Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
University of Maryland, Baltimore
Fate Therapeutics
Shanghai Junshi Bioscience Co., Ltd.
Wake Forest University Health Sciences
Acepodia Biotech, Inc.
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Mayo Clinic
Chinese PLA General Hospital
Adicet Therapeutics
Peking University Cancer Hospital & Institute
University of Chicago
National Institutes of Health Clinical Center (CC)
CARGO Therapeutics
Columbia University
Miltenyi Biomedicine GmbH